Press Releases
 
Fungal Infections - Pipeline Analysis 2018

United States, 14 February 2018 -- Fungal Infection is a major cause of morbidity worldwide. Fungal Infections are caused by different fungi found in environment. Although, some fungi are not dangerous at all but few types of fungi are harmful to health. It involves the invasion of tissue such as skin and lung by specific type of fungi.

According to Centers for Disease Control and Prevention (CDC), a public health institute in the U.S., approximately 1.5 million different species of fungi are present on earth. Out of them, 300 fungi species cause fungal infection in humans. Fungal Infection Trust, a U.K. based organization for the improvement of quality of life of fungal infected patient observed that approximately billion people are affected by fungal infection every year. It is most common among people who are using antineoplastic agents, immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices. Patients with HIV infection, burns, neutropenia and pancreatitis are at high risk of developing fungal infection.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis/report-sample

The fungal infection pipeline has more than 60 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.

VB 2862 is a pre-clinical drug candidate of Vyom Biosciences for the treatment of recalcitrant tinea infections. The company is using molecular replacement therapy platform for the development of VB 2862. Preclinical study is also known as animal study. It is done before testing a drug in people to find out the toxicity profile of the drug. Preclinical study is of two types, including in vitro and in vivo.

Browse Other Related report at: https://www.psmarketresearch.com/industry-report/pharmaceuticals

Pipeline analysis provides description about the key companies developing fungal infections drugs. Some of the key players actively involved in the research and development are Moberg Pharma AB, Viamet Pharmaceuticals, Inc., Pulmocide Ltd., Vyom Biosciences, NovaDigm Therapeutics Inc., Matinas BioPharma Holdings Inc., Sol-Gel Technologies Ltd. and Eisai Co. Ltd.

# # #


Submitted by Jacob, P&S Market Research on Wednesday, 14 February 2018 at 8:35 PM
Category: Health Care & Medical
 
Related News

Global Lymphoblastic Lymphoma Clinical Trials Market Outlook to 2017: Ken Research
Friday, 23 Feb 2018

Lymphedema Global Clinical Trials Review H2 2017: Ken Research
Friday, 23 Feb 2018

Rheumatology Therapeutics Market will Rise at a Lackluster CAGR of 2.7% from 2017 to 2025
Friday, 23 Feb 2018

General Surgery Devices Market : Competitive Landscape Analysis with Forecast by 2025
Friday, 23 Feb 2018

Drug and Alcohol Rehabilitation Market : Competitive Landscape Analysis with Forecast by 2025
Friday, 23 Feb 2018

Related Events

The 5th International Congress on Cardiac Problems in Pregnancy (CPP 2018)
Thursday, 22 Feb 2018

Winter Wilderness First Aid Certification - Colorado
Friday, 23 Feb 2018

Collaborative 3D Printing in Medical Practice
Friday, 23 Feb 2018

The Great Plains Laboratory Presents GPL Academy Practitioner Workshops
Saturday, 24 Feb 2018

Taking Care Over the Long Haul: Improving Diabetes Management, Atlanta 2018
Saturday, 24 Feb 2018

Latest News

African Print Fabric - Lovely and Distinct Styles
Saturday, 24 Feb 2018

Gino Venoroso Promoted To the Position of Area Manager of Business Development for Sunrise Senior Li
Saturday, 24 Feb 2018

Josh Patton, Josh, and Theresa Wegner Has Posted a Project for Animo Card Game at Kickstarter
Friday, 23 Feb 2018

S.O.S Loans Allowing PayPal Payments for Its Personal Loans
Friday, 23 Feb 2018

Meta Xylylene Diamine Market Business is Booming. Asia-Pacific is expected to Experience the Fastest
Friday, 23 Feb 2018

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2018
Today is Saturday, 24 February 2018

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • What should be paid attention to in the ultrafine grinding process?
  • The 5th International Congress on Cardiac Problems in Pregnancy (CPP 2018)
  • Winter Wilderness First Aid Certification - Colorado
  • Collaborative 3D Printing in Medical Practice
  • Taking Care Over the Long Haul: Improving Diabetes Management, Atlanta 2018

  • Latest Jobs
    Sorry, there are currently no entries posted here.